Actinium Pharmaceuticals, Inc. (ATNM) Return on equity 2021–2025
Actinium Pharmaceuticals, Inc. (ATNM) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-432.6%FY2025 · since FY2021: -33.7% → -432.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -432.6% | — |
| FY2023 | -134.2% | -84.5 pp |
| FY2022 | -49.7% | -16.0 pp |
| FY2021 | -33.7% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More ATNM financial trends
ATNM RevenueATNM Net incomeATNM Net marginATNM Gross profitATNM Gross marginATNM Operating incomeATNM Operating marginATNM Operating cash flowATNM Free cash flowATNM Capital expendituresATNM Stock buybacksATNM Dividends paidATNM Total assetsATNM Total liabilitiesATNM Shareholders’ equityATNM overview →